News

FDA approves first Phase 1 study of an embryonic stem cell therapy

Country
United States

Geron Corporation of Menlo Park, California, has announced that its application to test an embryonic stem cell therapy for spinal cord injury in humans has been approved by the US Food and Drug Administration. It is the first regulatory approval of a human trial involving embryonic stem cells, which have the ability to differentiate into any of the more than 200 specialised cells in the human body.

Roundup of recent legal and IP news

Country
United Kingdom

Geneart receives European protein patent

Geneart AG has been granted a European patent describing a method for carrying out the selective identification of proteins in vitro. The patent, EP 1913140, underpins the company’s proprietary technology platform relating to the generation and screening of proteins. According to the company, these proteins could become the basis for new therapeutics, vaccines and industrial enzymes. Geneart said its procedure makes it possible to identify optimal variants of a protein from a considerably larger pool more quickly than with conventional methods. This increases the probability of identifying an ideal protein variant such as a strong-binding antibody for a cancer therapy. The European Patent Office granted the patent on 24 December 2008.

Oxford BioMedica says patent suit brought by Bavarian Nordic is dismissed

Country
United Kingdom

Oxford BioMedica Plc said that a patent infringement suit brought against it by Bavarian Nordic A/S of Denmark has been dismissed. The suit alleged that the UK company had infringed three of Bavarian Nordic’s US patents for a viral vector used in the Danish company’s smallpox, HIV and cancer programmes.

EMEA installs its sixth scientific committee

Country
United Kingdom

The European Medicines Agency has installed a new specialist committee which will review for the first time, applications from companies developing gene therapies, cell-based products and therapies that are engineered from human and/or animal tissue.

Pronova BioPharma slims down management

Country
Norway

Following the appointment of Per-Oluf Olsen as chief executive officer in November 2008, Pronova BioPharma of Norway has reduced the size of its top management team.